Approved drugs are statins, PCSK9 Inhibitors, Bempedoic acid, inclisiran, while a number of pipeline drugs are being investigated. According to some available research, the market in the seven ...

CAMBRIDGE, Mass., April 01, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...

1.1 This document describes the funding and supply arrangements for inclisiran (Leqvio®) as an option in the lipid management pathway. These arrangements follow from the recommendations NICE set out ...

To ensure that a full range of lipid management treatments is available, we have renegotiated an agreement with Novartis for continued access to inclisiran, maintaining the same price for current and ...

Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the ...

The study enrolled 320 patients, dividing them into three dosing groups receiving a single dose of either 16mg, 96mg, or 400mg at the point of baseline measurement. Credit: Shutterstock / Dmytro ...

Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration ...

As a small interfering RNA (siRNA) drug, Qfitlia mimics a natural cellular process that regulates gene expression. By suppressing antithrombin (AT), a protein that inhibits blood clotting ...

However, miRNA can be used as targets or biomarkers for other treatments. siRNA: short strands of RNA that are also part of the RNA interference pathway, however, are specific to a single target mRNA.

With the FDA approval of multiple siRNA-based drugs, including ONPATTRO™ (Patisiran) and Inclisiran, the field is witnessing rapid advancements in delivery platforms, stability, and tissue ...